NCG-MHC-dKO Mice

The NCG-MHC-dKO is a triple immunodeficient NCG mouse that lacks expression of the MHC class I molecule (H2-K and H2-D1), and MHC class II molecule (H2-Ab1). Lack of expression of MHC I and MHC II leads to a significant delay in the onset of graft-versus-host disease (GVHD) in PBMC humanized NCG models.OriginThe NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain by knocking out MHC I and II expression creating the NCG-MHC-dKO. The strain was transferred to Charles River in 2023.